

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/716,163 Confirmation No. 3896
Applicants: Ricardo Mayo-Alvarez et al.
Filed: November 17, 2003
TC/A.U.: 1655
Examiner Michelle Flood
Docket No.: 5009-1
Customer No.: 22442
For: "Pharmaceutical Composition"

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450


STATEMENT OF THE SUBSTANCE OF THE INTERVIEW

Sir,

Applicant's representative conducted a telephonic interview with Examiner Flood on 11 December 2006. The Examiner now requires a Statement of the substance of the interview. As no further Amendment or Response is anticipated prior to the payment of the issue fee, this statement is filed to meet Applicant's duty to file the summary of the interview.

Applicants representative and Examiner Flood discussed the format and scope of claims for possible divisional or continuation applications claiming priority to this application. Specifically, the effect of the Lazarus article, which is of record in the prosecution of the instant application, was discussed with respect to an embodiment of the invention including the opiate oxycodone as opposed to hydrocodone and the effect of the Lazarus' teaching an oxycodone dosage that is generally outside the therapeutically recognized range. The Examiner indicated that this dosage range may be merely the product of routine experimentation despite Lazarus teaching away from this dosage range.

Respectfully submitted,
SHERIDAN ROSS P.C.

By: 
Robert D. Traver
Registration No. 47,999
1560 Broadway, Suite 1200
Denver, Colorado 80202-5141
(303) 863-9700

Date: January 2, 2007